目的 探讨血清长链非编码RNA(LncRNA)浆细胞瘤可变易位基因1(PVT1) ，LncRNA H19表达与前列腺癌患者术后复发转移的关系。方法 选取2016年8月～2018年8月我院收治的169例前列腺癌患者为前列腺癌组，统计术后3年复发转移率，另选取同期74例体检健康者为对照组，qRT-PCR检测血清LncRNA PVT1，LncRNA H19表达。多因素Cox回归分析前列腺癌患者术后复发转移影响因素。ROC曲线分析血清LncRNA PVT1，LncRNA H19表达对前列腺癌患者术后复发转移的预测价值。结果 与对照组比较，前列腺癌组血清LncRNA PVT1，LncRNA H19表达升高(P＜0.05)。中位随访22个月，169例结肠癌患者截止末次随访术后复发转移66例，与未复发转移组比较，复发转移组血清LncRNA PVT1，LncRNA H19表达升高(P＜0.05)。多因素Cox回归分析显示，TNM分期Ⅲ期(HR=3.722，95%CI:1.416～7.784，P=0.008)、Gleason评分≥7分(HR=4.626，95%CI:1.670～9.815，P=0.003)、LncRNA PVT1(HR=1.982，95%CI:1.521～2.584，P＜0.001)，LncRNA H19(HR=1.868，95%CI:1.327～2.630，P＜0.001)为前列腺癌患者术后复发转移的独立危险因素。ROC曲线显示，LncRNA PVT1，LncRNA H19，LncRNA PVT1＋LncRNA H19预测前列腺癌患者术后复发转移的曲线下面积分别为0.768、0.799、0.892，敏感度分别为93.94%、59.09%、81.82%，特异度分别为46.60%、89.32%、83.50%，LncRNA PVT1＋LncRNA H19预测前列腺癌患者术后复发转移的曲线下面积大于各指标单独预测(P＜0.05)。结论 前列腺癌患者血清LncRNA PVT1，LncRNA H19高表达，为术后复发转移的独立危险因素，可作为前列腺癌患者术后复发转移预测指标。
【Objective】To investigate the relationship between serum long-stranded non-coding RNA (LncRNA) plasmacytoma variant translocation 1 (PVT1), LncRNA H19 expression and postoperative recurrence and metastasis in prostate cancer patients. 【Methods】 169 prostate cancer patients admitted to our hospital from August 2016 to August 2018 were selected as the prostate cancer group, and the recurrence and metastasis rate at 3 years after surgery was counted. 74 healthy individuals with physical examination during the same period were also selected as the control group, and serum LncRNA PVT1, LncRNA H19 expression were detected by qRT-PCR. Multi-factor Cox regression was used to analyze the factors influencing recurrent metastasis in prostate cancer patients after surgery. The ROC curve was used to analyze the predictive value of serum LncRNA PVT1, LncRNA H19 expression on postoperative recurrent metastasis in prostate cancer patients. 【Results】 Serum LncRNA PVT1, LncRNA H19 expression was increased in the prostate cancer group compared to the control group (P＜0.05). At a median follow up of 22 months, 169 patients with colon cancer recurred and metastasized 66 cases as of the last follow up. Compared with the group without recurrence and metastasis, the expression of serum LncRNA PVT1 and LncRNA H19 was increased in the recurrence and metastasis group (P＜0.05). Multifactorial Cox regression analysis showed that TNM stage III (HR=3.722, 95%CI: 1.416 to 7.784, P=0.008), Gleason score ≥7 (HR=4.626, 95%CI: 1.670 to 9.815, P=0.003), LncRNA PVT1 (HR=1.982, 95%CI: 1.521 to 2.584, P＜0.001), and LncRNA H19 (HR=1.868, 95%CI: 1.327 to 2.630, P＜0.001) as independent risk factors for postoperative recurrent metastasis in prostate cancer patients. The ROC curves showed that the areas under the curves of LncRNA PVT1, LncRNA H19, and LncRNA PVT1＋LncRNA H19 for predicting postoperative recurrent metastasis in prostate cancer patients were 0.768, 0.799, and 0.892, respectively, with sensitivities of 93.94%, 59.09%, and 81.82%, and specificities of 46.60%, 89.32%, and 83.50%, respectively. The area under the curve of LncRNA PVT1＋LncRNA H19 predicting postoperative recurrent metastasis in prostate cancer patients was greater than that predicted by each index alone (P＜0.05).